Anti-TNF biosimilars: Exploring the possibilities
Listen to our expert-led podcast series on anti-tumour necrosis factor (TNF) biosimilars in rheumatic disease, looking at anti-TNF best practice and the impact of biosimilars for patients and healthcare professionals.
Episode 1 – Biological DMARDs: Medication and patient considerations
Hear about the armamentarium of biological therapies available for the treatment of rheumatic disease, including biological DMARDs (disease-modifying antirheumatic drugs), and how they may slow the progression of arthritis. Professor Peter Taylor and Professor Rieke Alten discuss how different anti-TNFs may better suit different patients and the issue of anti-drug antibodies.
Episode 2 – ‘Don’t hesitate’: Biosimilars for rheumatoid arthritis
“The complexity of a biologic molecule is such that it’s impossible to make exact copies.” Professor Peter Taylor and Professor Hans Bijlsma consider anti-TNF biosimilars – the regulatory process, guidelines, uptake within healthcare systems and the resulting impact on patient health and wellbeing.
If you enjoyed watching these introductory videos, check out our four EACCME®-accredited episodes, in which more experts join Professor Peter Taylor to discuss key topics in depth, including using biosimilars as a first- line biological treatment for rheumatoid arthritis, the importance of early intervention, and non-medical switching in clinical practice.
Professor Peter Taylor
Professor Peter Taylor holds the Norman Collison Chair of Musculoskeletal Sciences at the University of Oxford, UK, and is a Fellow of St Peter’s College, Oxford. He is the Director of Experimental Rheumatology at the Botnar Research Centre within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences. He is also Chief Medical Advisor to the National Rheumatoid Arthritis Society, a patient-led charity that works to support patients with rheumatoid arthritis and juvenile inflammatory arthritis.
Professor Taylor has over 30 years of experience in clinical trial design and international leadership in studies of biologic and small molecular therapies in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, including the earliest seminal trails of anti-TNF and anti-interleukin-6 receptor therapy.
Disclosures - Professor Taylor has received research grants from Celgene and Galapagos, and consultation fees from AbbVie, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Novartis, Pfizer, Roche, Sanofi, and UCB.
Professor Rieke Alten
Professor Rieke Alten is a Professor of Medicine and Head of the Department of Internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik, University Medicine Berlin, Germany, where she also serves as the Director of the Rheumatology Research Center. Professor Alten’s research interests focus on the development and systematic evaluation of biological and immunomodulatory treatments for rheumatic diseases. She has been the principal investigator for over 100 clinical trials of novel therapies in rheumatic diseases and has contributed to several investigator-initiated trials. Professor Alten has published over 200 original papers, book chapters and reviews.
Professor Alten’s research interests focus on the development and systematic evaluation of biological and immunomodulatory treatments for rheumatic diseases. She has been the principal investigator for over 100 clinical trials of novel therapies in rheumatic diseases and has contributed to several investigator-initiated trials. Professor Alten has published over 200 original papers, book chapters and reviews.
Disclosures - Professor Alten has received honoraria from AbbVie, Biogen, Bristol Myers Squibb, Celltrion, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Roche-Chugai, UCB, and Viatris. She has also received research grants from Bristol Myers Squibb, Galapagos, Lilly, Novartis, and Pfizer.
Professor Hans Bijlsma
Professor Johannes (Hans) Bijlsma is Emeritus Professor of Rheumatology at the University of Utrecht in the Netherlands. He has previously served as President of EULAR (2017–2019) and the Dutch Society for Rheumatology (1996–1999), and on the editorial boards of multiple medical journals. He is an author or co-author of over 850 articles published in peer-reviewed international journals and is an editor or chapter author of multiple books on rheumatology.
Professor Bijlsma’s research interests cover immune aspects of rheumatic diseases, treatment strategies in early rheumatoid arthritis, glucocorticoids and osteoarthritis.
Disclosures - Over the past 2 years, Professor Bijlsma has received speaker and/or consultancy fees from Fresenius, Galapagos, and UCB.
of interest
are looking at
saved
next event
Developed by EPG Health, for Medthority. This content has been developed independently of the sponsor, Sandoz, who has had no editorial input into the content. Medthority received unrestricted educational grant funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information and associated relevant content, without any promotional intent. This content is intended for healthcare professionals only.